The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
